Passionate about healthcare innovation and profoundly interested in transformative and affordable medicines. I am engaged in advising life sciences companies to develop innovative and differentiating assets that address unmet medical needs and provide value to the benefit of patients.
Entrepreneurial scientist and seasoned C-level executive in international life sciences industry and biopharma. Business acumen and relevant accomplishments at pre-clinical and clinical stages, up until submission and approval of products. Result-driven leader familiar with key scientific, medical, technical, regulatory and commercial success factors in the healthcare sector (ex SANOFI, Novartis, Glenmark, NDA-SSI).
Track record in discovery, clinical and technical development of innovative medicines for treatment of immune-mediated diseases (auto-immunity, immuno-oncology). Scientific background in immunology, biotechnology and chemistry (Basel, Max-Planck Munich, UCSF Medical Center, ETH Zurich). Executive programs at Harvard Business School, INSEAD and IMD.
Doer profile with 25+ years of hands-on experience in running innovative product pipelines (ranging from early discovery through phase 3 support and marketed products) including biopharmaceuticals and small molecule therapeutics. Management of large multi-site units and breakthrough collaborative networks between biopharma and biotech/academia. Kurt’s passion is to actively drive therapeutic innovation in healthcare, and the ongoing transformation process of current therapy concepts towards more personalised and digitalised medicine.
Kurt is a healthcare advisor at present, engaged in key mandates with distinct value proposition to healthcare partners including developers of innovative medicines, payers and regulators. He supports pharmaceutical companies, biotech start-up's, NGO's and investors.